| Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib C Sun, X Tian, YS Lee, S Gunti, A Lipsky, SEM Herman, D Salem, ... Blood, The Journal of the American Society of Hematology 126 (19), 2213-2219, 2015 | 243 | 2015 |
| Disruption of in vivo Chronic Lymphocytic Leukemia Tumor–Microenvironment Interactions by Ibrutinib – Findings from an Investigator-Initiated Phase II Study CU Niemann, SEM Herman, I Maric, J Gomez-Rodriguez, A Biancotto, ... Clinical Cancer Research 22 (7), 1572-1582, 2016 | 225 | 2016 |
| Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study IE Ahn, MZH Farooqui, X Tian, J Valdez, C Sun, S Soto, J Lotter, S Housel, ... Blood, The Journal of the American Society of Hematology 131 (21), 2357-2366, 2018 | 223 | 2018 |
| Incidence and risk factors of bleeding-related adverse events in patients with chronic lymphocytic leukemia treated with ibrutinib AH Lipsky, MZH Farooqui, X Tian, S Martyr, AM Cullinane, K Nghiem, ... Haematologica 100 (12), 1571, 2015 | 196 | 2015 |
| The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy DA Landau, C Sun, D Rosebrock, SEM Herman, J Fein, M Sivina, ... Nature communications 8 (1), 2185, 2017 | 195 | 2017 |
| Anal fistula plug and fibrin glue versus conventional treatment in repair of complex anal fistulas W Chung, P Kazemi, D Ko, C Sun, CJ Brown, M Raval, T Phang The American Journal of Surgery 197 (5), 604-608, 2009 | 148 | 2009 |
| Direct in vivo evidence for increased proliferation of CLL cells in lymph nodes compared to bone marrow and peripheral blood TM Herndon, SS Chen, NS Saba, J Valdez, C Emson, M Gatmaitan, ... Leukemia 31 (6), 1340-1347, 2017 | 143 | 2017 |
| Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines C Pleyer, MA Ali, JI Cohen, X Tian, S Soto, IE Ahn, EM Gaglione, ... Blood, The Journal of the American Society of Hematology 137 (2), 185-189, 2021 | 130 | 2021 |
| Molecular map of chronic lymphocytic leukemia and its impact on outcome BA Knisbacher, Z Lin, CK Hahn, F Nadeu, M Duran-Ferrer, KE Stevenson, ... Nature genetics 54 (11), 1664-1674, 2022 | 115 | 2022 |
| A CD19/CD3 bispecific antibody for effective immunotherapy of chronic lymphocytic leukemia in the ibrutinib era HR Robinson, J Qi, EM Cook, C Nichols, EL Dadashian, C Underbayev, ... Blood, The Journal of the American Society of Hematology 132 (5), 521-532, 2018 | 113 | 2018 |
| Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib C Sun, P Nierman, EK Kendall, J Cheung, M Gulrajani, SEM Herman, ... Blood, The Journal of the American Society of Hematology 136 (1), 93-105, 2020 | 104 | 2020 |
| Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia M Shapiro, Y Herishanu, BZ Katz, N Dezorella, C Sun, S Kay, A Polliack, ... Haematologica 102 (5), 874, 2017 | 98 | 2017 |
| Seasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with ibrutinib C Sun, J Gao, L Couzens, X Tian, MZ Farooqui, MC Eichelberger, ... JAMA oncology 2 (12), 1656-1657, 2016 | 87 | 2016 |
| NX-2127-001, a first-in-human trial of NX-2127, a Bruton's tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B … AR Mato, WG Wierda, WZ Ai, IW Flinn, M Tees, MR Patel, K Patel, ... Blood 140 (Supplement 1), 2329-2332, 2022 | 65 | 2022 |
| Harnessing the effects of BTKi on T cells for effective immunotherapy against CLL M Mhibik, A Wiestner, C Sun International journal of molecular sciences 21 (1), 68, 2019 | 53 | 2019 |
| Overcoming acquired epigenetic resistance to BTK inhibitors AL Shaffer III, JD Phelan, JQ Wang, DW Huang, GW Wright, M Kasbekar, ... Blood cancer discovery 2 (6), 630-647, 2021 | 49 | 2021 |
| Outcomes of anal fistula surgery in patients with inflammatory bowel disease W Chung, D Ko, C Sun, MJ Raval, CJ Brown, PT Phang The American journal of surgery 199 (5), 609-613, 2010 | 48 | 2010 |
| Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients JR Brown, JC Byrd, P Ghia, JP Sharman, P Hillmen, DM Stephens, C Sun, ... Haematologica 107 (6), 1335, 2021 | 47 | 2021 |
| Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies RR Furman, JC Byrd, RG Owen, SM O’Brien, JR Brown, P Hillmen, ... Leukemia 35 (11), 3201-3211, 2021 | 46 | 2021 |
| Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia LM Saleh, W Wang, SEM Herman, NS Saba, V Anastas, E Barber, ... Leukemia 31 (2), 340-349, 2017 | 45 | 2017 |
